NovoCure (NVCR) Set to Announce Quarterly Earnings on Wednesday

NovoCure (NASDAQ:NVCR) is set to issue its quarterly earnings data before the market opens on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.09. The business had revenue of $150.40 million for the quarter, compared to the consensus estimate of $135.83 million. NovoCure had a negative return on equity of 45.68% and a negative net margin of 30.67%. The business’s quarterly revenue was up 19.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.54) earnings per share. On average, analysts expect NovoCure to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NovoCure Stock Down 0.7 %

NovoCure stock opened at $16.15 on Wednesday. NovoCure has a 1-year low of $10.87 and a 1-year high of $24.74. The business has a fifty day moving average price of $16.98 and a 200-day moving average price of $17.80. The company has a debt-to-equity ratio of 1.81, a current ratio of 6.46 and a quick ratio of 6.22. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -8.92 and a beta of 0.70.

Analysts Set New Price Targets

NVCR has been the topic of several recent analyst reports. HC Wainwright upgraded shares of NovoCure from a “neutral” rating to a “buy” rating and upped their price objective for the company from $24.00 to $30.00 in a report on Wednesday, October 16th. Wells Fargo & Company decreased their price target on shares of NovoCure from $42.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, July 26th. Wedbush reissued an “outperform” rating and issued a $24.00 target price on shares of NovoCure in a research report on Thursday, July 25th. Finally, Evercore ISI lowered their price target on NovoCure from $21.00 to $18.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, NovoCure currently has an average rating of “Moderate Buy” and a consensus price target of $26.17.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.